Find NCI Program Director Contacts for the following Divisions, Centers, and Offices
NCI Divisions
- Division of Cancer Biology (DCB)
- Division of Cancer Control and Population Sciences (DCCPS)
- Division of Prevention (DCP)
- Division of Cancer Treatment and Diagnosis (DCTD)
Centers, Offices, and Selected Programs
- Center for Cancer Training (CCT)
- Center to Reduce Cancer Health Disparities (CRCHD)
- Center for Strategic Scientific Initiatives (CSSI)
- Office of Biorepositories and Biospecimen Research (OBBR)
- Office of Cancer Clinical Proteomics (OCCPR)
- The Cancer Genome Atlas Program Office (TCGA)
- Office of Cancer Genomics (OCG)
- Office of HIV and AIDS Malignancies (OHAM)
- Innovative Molecular Analysis Technologies Program (IMAT)
- Office of Nanotechnology Research (OCNR)
- Office of Physical Sciences Oncology (OPSO)
- Provocative Questions Program (PQ)
- Small Business & Small Business Technology Transfer (SBIR/STTR)
NCI Divisions
Division of Cancer Biology
DCB supports and coordinates research projects in basic cancer biology at universities, hospitals, research foundations, and businesses across the United States and abroad.
DCB Staff Directory 1
Cancer Cell Biology 2 Integrative Cancer Biology Program 6 | Mouse Models of Human Cancers Consortium 7 Tumor Biology and Metastasis 9 Tumor Microenvironment Network 10 |
Division of Cancer Control & Population Sciences
DCCPS supports a comprehensive program of genetic, epidemiologic, behavioral, social, and surveillance cancer research.
DCCPS Staff Directory 11
Division of Cancer Prevention
DCP supports research to determine and reduce a person's risk of developing cancer, as well as research to develop and evaluate cancer screening procedures.
DCP Staff Directory 30
| Biometry 31 Dr. Philip Prorok 301-496-7709 prorokp@mail.nih.gov Breast and Gynecologic Cancer 32 Dr. Terri Cornelison 301-402-3963 cornelit@mail.nih.gov Cancer Biomarkers 33 Dr. Sudhir Srivastava 301-496-3983 srivasta@mail.nih.gov Chemopreventive Agent Development 34 Dr. Vernon Steele 301-594-0420 steelev@mail.nih.gov Community Oncology & Prevention Trials 35 Dr. Lori Minasian 301-594-7868 minasilo@mail.nih.gov | Early Detection 36 Dr. Christine Berg 301-496-1071 bergc@mail.nih.gov Gastrointestinal and Other Cancers 37 Dr. Asad Umar 301-594-7671 umara@mail.nih.gov Lung and Upper Aerodigestive Cancer 38 Dr. Eva Szabo 301-435-2456 szaboe@mail.nih.gov Nutritional Science 39 Dr. John Milner 301-496-0118 milnerj@mail.nih.gov Prostate and Urologic Cancer 40 Dr. Howard Parnes 301-402-3606 parnesh@nih.gov |
Division of Cancer Treatment and Diagnosis
DCTD supports the translation of promising research areas into improved diagnostic and therapeutic interventions for cancer patients.
DCTD Staff Directory 41
| Cancer Diagnosis Program 42 Dr. Barbara Conley 301-496-8639 barbara.conley@nih.gov Cancer Imaging Program 43 Dr. Paula Jacobs 301-435-9181 jacobsp@mail.nih.gov Cancer Therapy Evaluation Program 44 Dr. Jeffrey Abrams 301-496-2522 abramsj@ctep.nci.nih.gov Developmental Therapeutics Program 45 Dr. Jerry Collins 301-496-8720 collinsje@mail.nih.gov | Complementary and Alternative Medicine 46 Dr. Jeffrey D. White 301-435-7980 jeffreyw@mail.nih.gov Radiation Research Program 47 Dr. C. Norman Coleman 301-496-6111 coleman@mail.nih.gov Translational Research Program (including SPOREs) 48 Dr. Toby Hecht 301-435-9043 hechtt@mail.nih.gov |
NCI Centers, Offices, and Programs
Find NCI Program Director contacts for the following NCI Centers, Offices, and Selected Programs.
Center for Cancer Training (CCT) 49
CCT provides funding to support training and career development for cancer researchers working at institutions nationwide and also manages intramural training programs offered at NCI laboratories and offices.
Center to Reduce Cancer Health Disparities 50
CRCHD supports the reduction of cancer health disparities in diverse populations through research, training, and partnerships.
Center for Strategic Scientific Initiatives 51
CSSI provides support for innovative programs that include nanotechnology, clinical proteomics, biorepositories and biospecimens, and physical sciences cancer research.
Office of Biorepositories and Biospecimen Research 52
OBBR coordinates and manages the development of biospecimen-related policies and practices affecting NCI biorepositories.
Office of Cancer Clinical Proteomics 53
OCCPR supports the development of technologies and reagents that will advance our understanding of protein biology in cancer
The Cancer Genome Atlas Program 54
TCGA is a NCI initiative aimed at accelerating our understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing.
Office of Cancer Genomics 55
OCG supports programs that will enhance our understanding of the molecular mechanisms of cancer.
Office of HIV and AIDS Malignancies 56
OHAM coordinates HIV/AIDS research throughout the NCI, including programs in AIDS-related cancer.
Innovative Molecular Analysis Technologies Program 57
IMAT is a NCI initiative that supports the development of novel technologies that support clinical, laboratory, and epidemiology cancer research.
Office of Nanotechnology Research 58
OCNR directs the NCI Alliance for Nanotechnology in Cancer program that supports the application of nanotechnology to all aspects of cancer research.
Office of Physical Sciences-Oncology 59
OPSO supports the establishment of scientific teams and individual scientists from the fields of physics, mathematics, chemistry, and engineering to develop novel approaches for cancer research.
Provocative Questions Program 60
PQ is a NCI initiative that intends to assemble a list of important questions, or problems that are paradoxes in cancer research that will stimulate research communities to use laboratory, clinical, and population sciences in new, effective, and imaginative ways. Inquiries about the PQ program are being managed by the Center for Strategic Scientific Initiatives 61.
Small Business & Small Business Technology Transfer 62
SBIR and STTR programs seek to increase small business and private sector participation to develop and commercialize novel technologies to prevent, diagnose, and treat cancer.
Back to Top